High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up-Reference-Cited by-同舟云学术

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Published:2006-11-21 Issue:11 Volume:95 Page:1459-1466
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Villa L L,Costa R L R,Petta C A,Andrade R P,Paavonen J,Iversen O-E,Olsson S-E,Høye J,Steinwall M,Riis-Johannessen G,Andersson-Ellstrom A,Elfgren K,Krogh G von,Lehtinen M,Malm C,Tamms G M,Giacoletti K,Lupinacci L,Railkar R,Taddeo F J,Bryan J,Esser M T,Sings H L,Saah A J,Barr E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603469.pdf

Reference33 articles.

1. Ault K, Giuliano AR, Edwards R, Tamms G, Kim L-L, Smith JF, Jansen KU, Allende M, Taddeo F, Shulsky D, Barr E (2004) A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22: 3004–3007

2. Block S, Nolan T, Sattler C, Barr E, Giacoletti KED, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118: 2133–2145

3. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244–265

4. Chan ISF, Bohidar NR (1998) Exact power and sample size for vaccine efficacy studies. Theory Methods 27: 1305–1322

5. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, Anh PTH, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CLLM, Franceschi S (2005) Worldwide distribution of HPV types in cytologically normal women: Pooled analysis of the IARC HPV prevalence surveys. Lancet 366: 991–998

Cited by 676 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time-resolved fluorescence (TRF) for total IgG and HPV16-specific antibody detection in first-void urine and serum: A comparative study;Journal of Virological Methods;2024-09

2. Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study;npj Vaccines;2024-08-13

3. The role of human papillomavirus in laryngeal cancer and recurrent respiratory papillomatosis: epidemiological and clinical aspects;Head and Neck Tumors (HNT);2024-08-04

4. IDENTIFYING PLAUSIBLE RANGES FOR DIFFERENTIAL VACCINE EFFICACY ACROSS HIGH- AND LOW-INCOME SETTINGS: A SYSTEMATIC REVIEW, DESCRIPTIVE META-ANALYSIS, AND ILLUSTRATIVE EVIDENCE ANALYSIS;2024-08-01

5. Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9–14 years at 5 years after vaccination;Vaccine;2024-05